Synapse - Gopakumar Iyer

Results (33)

Transcriptional analysis of bladder cancer histologic subtypes reveals novel drug target heterogeneity

Meeting Abstract

Tallman, J. E.; Kuo, F.; Koll, F.; Alam, S. M.; Basar, M.; Luo, J.; Gao, S. P.; Tang, X.; Yol, C.; Gokturk, G.; more...
Urologic Oncology: Seminars and Original Investigations (2025)

Fulltext@MSK | Save

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

Journal Article

Gillis, M. C.; Weir, V. R.; Lezcano, C.; Iyer, G.; Gordon, A.
JAAD Case Reports (2025)

Fulltext@MSK | Save

UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer

Meeting Abstract

Richardson, D.; Iyer, G.; Schmid, A.; Palma, N.; Navarro, W.; Ahnert, J. R.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)

Meeting Abstract

Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)

Meeting Abstract

Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations

Meeting Abstract

Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)